World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus speaks at the 73rd World Health Assembly (WHA) at the WHO headquarters in Geneva, Switzerland, May 18, 2020. (WHO/Handout via Xinhua)

"The Executive Group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine."

GENEVA, June 3 -- The World Health Organization (WHO) on Wednesday announced that based on the latest data review, the clinical trial of malaria drug hydroxychloroquine on COVID-19 patients will continue.

Speaking at a virtual press conference, WHO Director-General Tedros Adhanom Ghebreyesus said that experts have been reviewing the data and recommended that "there are no reasons to modify the trial protocol."

"The Executive Group received this recommendation and endorsed continuation of all arms of the Solidarity Trial, including hydroxychloroquine," he said.